Emerald Clinical Trials

Emerald Clinical Trials is a prominent global clinical research organization established in 2000. Formerly known as George Clinical, the firm rebranded in April 2025 to signify its expanded commitment to transparency and precision in clinical research. The company provides comprehensive end-to-end trial services, supporting biopharmaceutical, medical device, and diagnostic enterprises across all phases of development. By integrating scientific rigor with operational efficiency, the organization facilitates the advancement of medical innovation and the delivery of life-changing therapies to patients on a global scale.

Operating with a workforce of 500-1,000 employees, Emerald Clinical Trials maintains a robust presence across 40 geographical locations spanning Asia-Pacific, North America, and Europe. The firm leverages deep local expertise to manage complex trial requirements, including regulatory affairs, clinical trial monitoring, and patient recruitment. Meet Emerald Clinical Trials's team to understand the leadership driving these global operations. Their infrastructure supports over 100 biotech partners and six of the top ten global pharmaceutical firms, ensuring high-quality data management and safety reporting standards are consistently met throughout the trial lifecycle.

The organization possesses specialized expertise in renal research, having successfully executed over 80 studies across 50 countries. Beyond renal focus, Emerald Clinical Trials maintains significant capabilities in oncology and cardio-renal-metabolic therapeutic areas. By prioritizing patient-centered trial design and diverse population recruitment, the company accelerates study completion timelines. Their commitment to scientific excellence and reliable results continues to position them as a critical partner in the global healthcare ecosystem, advancing medical breakthroughs through data-driven clinical strategies.